Johnson & Johnson (JNJ) Holdings Lifted by Stratos Wealth Partners LTD.
Stratos Wealth Partners LTD. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 121,833 shares of the company’s stock after acquiring an additional 4,378 shares during the period. Johnson & Johnson makes up approximately 0.8% of Stratos Wealth Partners LTD.’s investment portfolio, making the stock its 23rd largest holding. Stratos Wealth Partners LTD.’s holdings in Johnson & Johnson were worth $16,117,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of the business. State Street Corp lifted its holdings in Johnson & Johnson by 4.3% during the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after acquiring an additional 6,656,371 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in Johnson & Johnson by 3.7% during the second quarter. Fisher Asset Management LLC now owns 11,499,415 shares of the company’s stock worth $1,521,258,000 after acquiring an additional 405,517 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Johnson & Johnson by 1.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 11,150,339 shares of the company’s stock worth $1,388,775,000 after acquiring an additional 201,703 shares in the last quarter. Clearbridge Investments LLC lifted its holdings in Johnson & Johnson by 3.4% during the first quarter. Clearbridge Investments LLC now owns 9,543,827 shares of the company’s stock worth $1,188,684,000 after acquiring an additional 310,831 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Johnson & Johnson by 0.5% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,948,942 shares of the company’s stock valued at $990,041,000 after purchasing an additional 42,144 shares in the last quarter. Hedge funds and other institutional investors own 66.06% of the company’s stock.
Johnson & Johnson (JNJ) opened at $139.56 on Friday. The firm has a market capitalization of $377,053.09, a P/E ratio of 19.66, a price-to-earnings-growth ratio of 2.85 and a beta of 0.82. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $144.35.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. The firm had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.68 earnings per share. equities analysts forecast that Johnson & Johnson will post 7.28 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.41%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.
JNJ has been the topic of a number of research reports. UBS AG restated a “buy” rating and issued a $148.00 price target (up from $136.00) on shares of Johnson & Johnson in a report on Wednesday, July 19th. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $148.00 price target on the stock in a report on Thursday, July 27th. Cowen and Company set a $147.00 price target on Johnson & Johnson and gave the company a “buy” rating in a report on Thursday, August 24th. Credit Suisse Group restated a “buy” rating on shares of Johnson & Johnson in a report on Friday, August 4th. Finally, BMO Capital Markets restated a “buy” rating and issued a $145.00 price target on shares of Johnson & Johnson in a report on Friday, September 1st. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $143.70.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.